Tech Company Financing Transactions
HBC Immunology Funding Round
HBC Immunology secured a $900 thousand Seed funding round on 8/17/2023. Backers included private investors.
Transaction Overview
Company Name
Announced On
8/17/2023
Transaction Type
Venture Equity
Amount
$900,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to commence preclinical animal trials with their patented peptides, FT-002 and FT-005. These are analogs of peptides discovered by HBC in ProGo® Bioactive Peptides which modulate iron metabolism and have Qualified Health claims granted for this mode of action, verifying their safety and efficacy. The objective of this round's use of proceeds is to demonstrate the bioactivity of the lead peptides in animal xenograft models of prostate cancer.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Undisclosed
Alesund, Undisclosed
NO
Alesund, Undisclosed
NO
Phone
Undisclosed
Email Address
Not Recorded
Overview
P6 provides software that paves the path to effective decarbonization through easy, and verifiable product-level life cycle analysis (LCA) of transportation fuels and petrochemicals
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bomi Framroze
Chief Medical Officer
Crawford Currie
Browse more venture capital transactions:
Prev: 8/17/2023: Jinx venture capital transaction
Next: 8/17/2023: D'Amelio Brands venture capital transaction
Share this article
News on VC Transactions
We document every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs